Dyslipidemias
Drug research and approvals for dyslipidemias: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 222 studies of dyslipidemias are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 222
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 5
- LIPI- PROTECT-2 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP2)NCT07948226 · Not applicable · Institut Pasteur de Lille · starts Nov 4, 2026
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated…NCT07937254 · Phase 1 · Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd. · starts Oct 19, 2026
- Cardiopulmonary Exercise Active Health Cohort StudyNCT07935187 · Not reported · Peking University Third Hospital · starts May 11, 2026
- Observational Study to Evaluate Achieving LDL-cholesterol Target Level to Treat With Rovazet Tab. With Dyslipidemia…NCT07924345 · Not reported · HK inno.N Corporation · starts May 22, 2024
- Asprosin and miRNA Expression in Young Women With Metabolic SyndromeNCT07917364 · Not reported · University of Applied Sciences in Nowy Targ · starts Nov 1, 2026
- Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 YearsNCT07880717 · Not reported · Mahidol University · starts Jul 1, 2026
- Evaluation of a New Virtual Care Pathway for Older Adults With Noncommunicable DiseasesNCT07843238 · Not applicable · National University of Malaysia · starts Sep 2, 2026
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseNCT07839936 · Phase 2 · Eli Lilly and Company · starts Sep 24, 2026
- Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary SyndromeNCT07824323 · Phase 4 · Taipei Medical University Hospital · starts Aug 26, 2026
Approved 9
- FenofibratePeroxisome proliferator-activated receptor alpha agonist
- PitavastatinHMG-CoA reductase inhibitor
- AtorvastatinHMG-CoA reductase inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- Icosapent ethyl
- AlirocumabSubtilisin/kexin type 9 inhibitor
- EvolocumabSubtilisin/kexin type 9 inhibitor
- Bempedoic acidATP-citrate synthase inhibitor
- Inclisiran sodiumPCSK9 mRNA rnai inhibitor
Phase 3 1
- DalcetrapibCholesteryl ester transfer protein inhibitor
Phase 1 or earlier 5
- ResmetiromThyroid hormone receptor beta-1 agonist
- ObicetrapibCholesteryl ester transfer protein inhibitor
- Solbinsiran sodium
- Zodasiran sodium
- Plozasiran sodium
How its trials ended
964 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 234 whose ending is known, 66% met their primary endpoint, 4% missed it and 30% stopped early.
- Completed, result not reported47549%
- Met its primary endpoint15516%
- Ongoing14115%
- Status unknown11412%
- Stopped: other or unclear424%
- Stopped: sponsor or business decision121%
- Missed its primary endpoint91%
- Stopped: enrollment or feasibility91%
- Stopped: lack of efficacy51%
- Stopped: funding2<1%
| Mar 26, 2021 | VazkepaIcosapent ethyl | Recordati Industria Chimica e Farmaceutica S.p.A. | EMA ↗ |
| Sep 23, 2015 | PraluentAlirocumab | Sanofi Winthrop Industrie | EMA ↗ |
| Jul 17, 2015 | RepathaEvolocumab | Amgen Europe B.V. | EMA ↗ |
| Aug 26, 2013 | CholibFenofibrate; simvastatin | Viatris Healthcare Limited | EMA ↗ |
| Apr 14, 2011 | PravafenixFenofibrate; pravastatin | Laboratoires SMB S.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA